cyrilzakka/clinical-trials huggingface dataset:
PNF With and Without Electrical Stimulation in Patients With Chronic Lumbar Radiculopathy

Numerous researches have shown how PNF is been used to treat non specific low back pain, subacromial impingement, cervical radiculopathy and many others. In some studies different techniques like Mckenzie method, spinal mobilization and Mulligan traction other than PNF were being used to treat lumbar radiculopathy. According to researchers knowledge little literature available to see the effectiveness of PNF with electrical stimulation in patients with chronic lumbar radiculopathy. Therefore, the purpose of the current study is to examine the effects of PNF with electrical stimulation in patients with chronic lumbar radiculopathy.


Eligibility Criteria:
Inclusion Criteria:

* • Diagnosed cases of lumbar radiculopathy

  * Either one or both legs affected by radiating pain
  * Signs of nerve root compression like paresthesia, numbness, tingling, sharp pain
  * Impaired deep tendon reflex(knee jerk, ankle jerk)
  * Both male and female
  * Radiological evidence of lumbar spondylosis with radiculopathy
  * Age group between 40 to 70 years
  * Positive SLR test between 45° to 70°
  * All subjects with symptoms for duration of more than 6 weeks
  * Increase leg pain by coughing and sneezing

Exclusion Criteria:

* Serious spinal conditions e.g infection, tumor, osteoporosis
* Uncontrolled hypertension
* Severe cognitive impairment
* Other neurological conditions and systemic illness like kidney and visceral diseases
* Vertebral fracture and spondylolisthesis
* Pregnant women
* History of spinal surgery in previous 6 months
* Clinical conditions such as oversensitive skin, patients with cardiac pacemakers where application of TENS is contraindicated
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

A randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and pioglitazone 30 mg after oral administration in healthy male subjects

A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study

Eligibility Criteria:
Inclusion Criteria:

* Healthy Male Volunteers (Age: 19\~45years)
* 55\<Body Weight\<90, 18\<BMI\<27
* FPG: 70-125 mg/dL

Exclusion Criteria:

* galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
* Clinically significant Medical History
* Allergy or Drug Hypersensitivity
* AST(SGOT), ALT(SGPT) \> Upper Normal Range\*1.5, eGFR\<80 mL/min
* Drink during clinical trial period
* Smoking during clinical trial period
* Grapefruit/Caffeine intake during clinical trial period
* No Contraception
SalT Reduction InterVEntion: Metabolic, Behavioral and Health Consequences of Reducing Salt in Bread

The trial is conducted as a randomized controlled trial including children and adults recruited as families. The families are randomly allocated into three groups to investigate the effect of different salt reduction strategies in a period of 3-4 months. Families in the first intervention group are receiving salt reduced bread. Families in the second intervention group are receiving salt reduced bread in combination with dietary counselling to reduce salt and increase potassium intake. Families in the control group are receiving bread with a regular content of salt and no dietary counselling.

The trial is conducted as a randomized controlled trial including children and adults recruited as families. The families are randomly allocated into three groups to investigate the effect of different salt reduction strategies in a period of 3-4 months. Families in the first intervention group are receiving salt reduced bread. Families in the second intervention group are receiving salt reduced bread in combination with dietary counselling to reduce salt and increase potassium intake. Families in the control group are receiving bread with a regular content of salt and no dietary counselling.

Participants will be instructed to replace their usual consumption of bread by the bread products provided in the study. In all other respects, participants will be requested to live their lives as usual without changing any habits, except the families receiving dietary counselling. The participants will be unaware of the treatment groups and the salt content of the bread products will be blinded to the participants.

Families will attend a physical examination at baseline and at 3-4 months follow-up. The health examination includes anthropometrics, blood pressure measurements and blood samplings for analysis of glucose, lipid metabolism and hormone balance. Urine samples will be collected to investigate the sodium and potassium content. Furthermore salt-sensitivity and preference tests will be made. After both health examinations the families will collect three repeated 24-hour urine collections at home and fill in a 7 days dietary record.

After data collection, blood and urine samples will be analysed. Analyses from both baseline and follow-up are expected ultimo February 2019, whereby data cleaning and statistical analyses will be performed.

Eligibility Criteria:
Inclusion Criteria:

* Participants living with children
* Adults 18-69 years
* Children 3-17 years
* Daily intake of bread

Exclusion Criteria:

* Diabetes
* Cardiovascular disease
* Antihypertensive treatment
* Lipid-lowering treatment
* Pregnancy
* U-albumin \> 300 mg/day
* Celiac disease
A Drug-drug Interaction Study of DP-R213

The purpose of this study is to learn about the effect of raloxifene on how the body absorbs and processes cholecalciferol and how cholecalciferol affects raloxifene when they are taken together.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male volunteer, age above 19
* The result of Ideal Body Weight(IBW) is not less than -20%, no more than +20%
* Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial.

Exclusion Criteria:

* Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment in completion of this clinical study
* Treatment history of other drugs within last 10 days
Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.

The purpose of this study is to identify the healing of aneurysms in three month use Optical Coherence Tomography image to measure outcomes in post coiled aneurysms. Endovascular therapeutic coiling is a widely used procedure in the management of aneurysms, which is an angiogram .

Subarachnoid hemorrhage secondary to ruptured cerebral aneurysms, unruptured aneurysms that are being treated using endovascular coiling. The researcher can use Optical Coherence Tomography image at the rime of initial angiography with unruptured aneurysms, and at the three month follow up catheter angiogram.

Optical Coherence Tomography image can follow the therapeutic coiling of the aneurysm, the 6F endocatheter and the microcatheter used for the coiling procedure place in the internal carotid artery and parent artery lumen follow with Optical Coherence Tomography fiber insert through the lumen of the tube on which the image can obtain.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years of age
* Subject diagnosis of aneurysm and undergoing endovascular coiling

Exclusion Criteria:

* Pregnant women
* Age ≤ 18 years of age
* Patient presenting emergently with acutely ruptured aneurysms
Antibiotic Prescribing Behavior Among French Intensivist: Construction and Validation of a Questionnaire

Antibiotic resistance is a major threat in modern medicine. Overuse of antibiotics is an important driver of antibiotic resistance. However, some authors have shown that up to 50% of antibiotic treatments in critically ill patients are inappropriate, mostly because they are used in patients with non-bacterial infections.

In order to improve antibiotic use, several antibiotic stewardship programs have been implemented worldwide. However, only few of them have taken into account the determinants of prescribing behaviors. Yet, these determinants have been shown to play a role among general practitioners of hospital doctors. Nevertheless, none of these factors have been studied among intensivists.

The current project represent phase 1 of the study : construction and validation of a questionnaire.

Antibiotic resistance is a major threat in modern medicine. Overuse of antibiotics is an important driver of antibiotic resistance. In critical care setting, antibiotic therapies are widely used due to the high number of patients presenting with sepsis. However, some authors have shown that up to 50% of antibiotic treatments in critically ill patients are inappropriate, mostly because they are used in patients with non-bacterial infections.

In order to improve antibiotic use, several antibiotic stewardship programs have been implemented worldwide. However, only few of them have taken into account the determinants of prescribing behaviors. Yet, these determinants have been shown to play a role among general practitioners of hospital doctors. Nevertheless, none of these factors have been studied among intensivists.

The study is designed to investigate social, cultural, contextual and personal factors influencing antibiotic prescribing among French intensivists. The design will consist of three phases:

* Phase 1: construction and validation of a questionnaire
* Phase 2: the questionnaire will be sent to all intensivist, including residents, in France
* Phase 3: qualitative study, based on semi-structured interviews.

The current project represent phase 1 of the study.

Eligibility Criteria:
Inclusion Criteria:

* Physicians with predominant intensive care practice
* Resident, with a minimum of two-month experience in the intensive care unit

Exclusion Criteria:

* Refusal to participate
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.

Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
* Participants must have folate receptor alpha positive tumor expression as defined in the protocol
* Participants must have platinum-resistant ovarian cancer, defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy.
* Participants must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment
* Participants must have at least one lesion that meets the definition of measurable disease by RECIST 1.1

Exclusion Criteria:

* Diagnosis of clear cell, low grade ovarian cancer or mixed tumors
* Participants with primary platinum-refractory disease
* Serious concurrent illness or clinically relevant active infection as defined in the protocol
* Prior treatment with mirvetuximab soravtansine
* Women who are pregnant or breast feeding
Re-invitation to Screening Colonoscopy: a Randomized Study

The aim of this study is to compare the effect of reminding letter and educational intervention on attendance to screening colonoscopy in nonresponders to initial invitation to screening colonoscopy.

NordICC (The NordICC Initiative on Colorectal Cancer, NCT00883792) is a multicenter randomised trial to investigate the effect of screening colonoscopy on CRC incidence and mortality. In Poland, in Warsaw area, at least 10,000 subjects 55-64 years of age are to be invited to screening colonoscopy. A personal letter of invitation containing date and hour of appointment is mailed to every individual randomised to the screening group. Up to 60% of invitees do not respond to the initial invitation and reminding letter. The aim of this study is to compare the effect of reminding letter and educational intervention on attendance to screening colonoscopy in nonresponders to initial invitation to screening colonoscopy.

Eligibility Criteria:
Inclusion Criteria:

* Men and women 55-64 years of age invited for screening colonoscopy within the NordICC trial (NCT00883792) in Poland, who have not responded to the first invitation.

Exclusion Criteria:

* Resident abroad
* Return of unopened letter of invitation and/or reminder (address unknown)
* Message from neighbour/family/post office on death of screenee (not updated in Population Registry).
Computer Vision Syndrome Prevalence Among University Students

CVS-F3 questionnaire will be used as an instrument to survey CVS prevalence and severity among medical students

CVS-F3 is a valid questionnaire that includes 26 questions to be responded by the medical students to detect CVS complains and possible complications. The questionnaire includes questions regarding potential ocular, extra-ocular, musclo-skeletal and neuro-psychatric complains caused by CVS. Complete statistical analysis of the survey data will be done using univariate and multivariate logistic and linear regression analysis.

Eligibility Criteria:
Inclusion Criteria:

* university students
* studying medicine

Exclusion Criteria:

* ocular surgery
* amblyopia
* anisometropia
* strabismus
* DM
* hypertension
Risk Factor of POD and POCD After Cardiac Surgery

Postoperative delirium (POD) and postoperative cognitive decline (POCD) are common after surgeries in the elderly, especially after cardiothoracic surgery. These conditions are associated with adverse short- and long-term outcomes.

Multiple conditions in the perioperative period have been proposed as risk factors of POD and POCD.

Incidences vary across institutions due to differences in screening and diagnostic tools.

This is a prospective observational study to identify the incidences and risk factors of postoperative delirium and postoperative cognitive decline after elderly patients undergoing cardiac surgical procedures which require cardiopulmonary bypass and postoperative intensive care unit (ICU) admission.

Patients will be screen for POD and POCD with various psychological tests in the postoperative period and after hospital discharge.

Perioperative data and outcomes will be used to identify risk factors of both conditions.

Eligibility Criteria:
Inclusion Criteria:

* age 65 years old or older
* undergoing open heart surgery (cardiopulmonary bypass assisted cardiothoracic surgery

Exclusion Criteria:

* unable to communicate
* severe visual or hearing impairment
Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound

to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream


Eligibility Criteria:
Inclusion Criteria:

* male and female probands age between 18-40 years
* skin healthy
* skintype I-III according to Fitzpatrick

Exclusion Criteria:

* women of childbearing potential without adequate contraception
* pregnant or breastfeeding
* genetic defect of epidermal barrier
* external or systemic treatment with drugs, which probably have an effect to the thickness of skin or to the production of teleangiektasien within the last 6 month before study entry
* skin disease, which hinder the evaluation with OCT, ultrasound or dermaphot
* UV treatment within the last 4 weeks before study entry
* participation to another clinical trial within the last 30 days before study entry
* allergy against pimecrolimus or hydrocortison or betamethasonvalerat or Clobetasol-17-propionat
* severe systemic diseases; ongoing immunosuppressive treatment
* planned vaccination should realize before study entry or 28 days after end of treatment
Home-Based Mental Health Evaluation (HOME)

The purpose of this project is to investigate the effectiveness of the Home-Based Mental Health Evaluation (HOME) program, which is an innovative and culturally-relevant suicide prevention intervention for Veterans aimed at increasing treatment engagement and decreasing suicide risk following psychiatric hospitalization, a period of heightened suicide risk.

The purpose of this project is to investigate the effectiveness of the Home-Based Mental Health Evaluation (HOME) program, which is an innovative and culturally-relevant suicide prevention intervention for Veterans aimed at increasing treatment engagement and decreasing suicide risk following psychiatric hospitalization, a period of heightened suicide risk. The research project employs a multi-site two-arm interventional trial design to study the effectiveness of the HOME program. Effectiveness of the treatment will be evaluated by comparing Veterans receiving the HOME program at two active treatment sites, Denver and Philadelphia Department of Veterans Affairs Medical Centers (VAMCs), to with those receiving care at two control sites, Houston and Portland VAMCs. The current protocol describes procedures as they will occur at all sites, including those completed locally at the Denver VAMC, which is the lead site for the study.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18-89
2. Able to provide a phone number and the location of a residence at which they can be reached
3. Planned location of discharge is a safe environment for the HOME provider to visit\*
4. Agree to receive the HOME program intervention (active site participants only)
5. Ability to adequately respond to questions regarding the informed consent procedure

Exclusion Criteria:

1. Receiving services from the Mental Health Intensive Case Management (MHICM) or Domiciliary program or being directly transferred to further inpatient or residential treatment
2. Enrolled in other intervention studies that may affect the outcome of this study, or where this study may affect the outcome of the other study, until the subject has completed their participation in the other study
3. Current involvement in the criminal justice system as a prisoner or ward of the state.
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).


Eligibility Criteria:
Inclusion Criteria for Urothelial Carcinoma Cohort:

* Patients with histologically confirmed metastatic urothelial carcinoma with extrapelvic nodal and/or visceral sites of disease (including lung, liver, bone, or soft tissue)
* At least 3 lesions assessable by FDG PET/CT according to RECIST and PERCIST guidelines where applicable, that are determined suspicious for metastasis by an MSKCC attending radiologist or nuclear medicine physician.
* Karnofsky performance status ≥50% (or ECOG/WHO ≤2)
* Participant is ≥18 years of age
* Patient must be able to understand and is willing to sign a written informed consent document

Inclusion Criteria for Melanoma Cohort:

* Patients with histologically confirmed metastatic melanoma
* At least 1 metastatic lesion assessable by CT or FDG PET/CT according to RECIST that is determined to be suspicious for metastasis by an MSKCC attending radiologist or nuclear medicine physician
* ECOG \<= 2
* Participant is \>= 18 years of age
* Patient must be able to understand and is willing to sign a written informed consent document

Exclusion Criteria for Urothelial Carcinoma Cohort:

* Patients with pelvic node-only metastatic disease. If the patient has lymph node only disease, at least one PET-assessable node must be located outside of the pelvis
* Patients with bone only disease
* Unable to lie flat, still, or to tolerate a PET scan
* Patient undergoing active treatment for non-urothelial malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized.
* Patients on a therapeutic clinical trial where PSMA imaging would interfere with the conduct of the trial
* Patients undergoing active surveillance with a known history of non-urothelial malignancies
* Women who are pregnant. All women of childbearing potential must have a documented negative pregnancy test.

Exclusion Criteria for Melanoma Cohort:

* Unable to lie flat, still, or tolerate PET scan.
* Patient is on another therapeutic trial where PSMA imaging would interfere with the conduct of the trial.
* Women who are pregnant. All women of childbearing potential must have a documented negative pregnancy test.
Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour

To assess the impact of four Patient Information Leaflets (PIL) on patient behaviour in primary care.

A patient who visited, for a gastroenteritis or a pharyngitis, one GP of the intervention group, received a Patient Information Leaflets (PIL) related to his disease and his age: either the gastroenteritis leaflet for adult or the one for child, either the pharyngitis leaflet for adult or the one for child.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient.
* Minor child accompanied by a responsible adult.
* The patient or the caregiver must be reachable by telephone within ten to fifteen days following the consultation.

Exclusion Criteria:

* Illiterate patient
* Patient refusing follow-up call.
* Patient with visual or hearing impairment.
* Patient non-Francophone.
* Private patient of liberty by judicial or administrative.
* Person being a measure of legal protection.